Navigation Links
FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
Date:4/22/2011

SILVER SPRING, Md., April 22, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra already is approved for use in people ages 2 through 55 years.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Meningococcal disease is a life-threatening illness caused by bacteria that infect the bloodstream (sepsis) and the lining that surrounds the brain and spinal cord (meningitis). Neisseria meningitidis is a leading cause of meningitis in young children. Even with appropriate antibiotics and intensive care, between 10 percent and 15 percent of people who develop meningococcal disease die from the infection. Another 10 percent to 20 percent suffer complications such as brain damage or loss of limb or hearing.

Although the rates of meningococcal disease are low in the United States, infants and toddlers are more susceptible to getting this serious illness. Meningococcal disease is particularly dangerous because it progresses rapidly and can cause death within hours. Early symptoms are often difficult to distinguish from influenza and other common illnesses.

"The highest rate of meningococcal disease occurs in children under one year of age. With today's approval, Menactra can now be used in children as young as 9 months of age to help prevent this potentially life-threatening disease," said Karen Midthun, M.D., director of FDA's Center for Biologics Evaluation and Research.

The safety of Menactra in children as young as 9 months was evaluated in four clinical studies in which over 3,700 participants received the vaccine. The most common adverse events reported in children who received Menactra at 9 months and 12 months of age were
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 /OFF ... Group LLC, PIV757417 The following release: "Biotech Advancements ... Drug Products & Treatments for Critical-Care Patients With ... time: 3 Aug 2015 12:30 GMT ... military surgical research and top-tier universities for identifying ...
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... ZIONA, Israel , August 3, ... TASE: BVXV) today announced it received the statistical analysis of ... vaccine (M-001), administered in the BVX-005 phase II trial which ... future strains which did not exist at the time of ... (flu) strain that caused the epidemic in the ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
... NEW YORK, April 13, 2012  Dr. David Samadi, leading ... prostate cancer survivors , and their families at the ... and detailed look at prostate cancer today, Dr. ... Robotic Technique) Surgery is so successful in treating the ...
... MIAMI BEACH, Fla., April 13, 2012  At the ... Scientific Meeting, April 14-18, at the Miami Beach ... innovations for Leksell Gamma Knife® Perfexion™ ... "Once again, AANS will give us the opportunity ...
Cached Medicine Technology:RoboticOncology.com News: SMARTer Prostate Cancer Treatment 2RoboticOncology.com News: SMARTer Prostate Cancer Treatment 3RoboticOncology.com News: SMARTer Prostate Cancer Treatment 4RoboticOncology.com News: SMARTer Prostate Cancer Treatment 5Elekta to Unveil New Neuroscience Solution for Leksell Gamma Knife at 2012 AANS Meeting 2
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, ... Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can help ... , Annually, more than 8.6 million adverse drug events are reported in ...
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... emergency dental services to help patients in need. Most people know that general health ... hospital emergency. Unfortunately, a fewer amount of people know where to turn to during ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, ... contract lifecycle management solution, as well as announced the date of its next ... and ease of contract management tasks as well as enhancements to the customer ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results ... Navigant Center for Healthcare Research and Policy Analysis show widespread support for the ... said they agreed or strongly agreed that the controversial law passed in 2010 ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
... could forewarn of climate change in 10 to 20 ... presented at a recent European Science Foundation (ESF) conference ... deep-water circulation, while a diluting of the waters results ... more important role that we first thought, said Prof. ...
... a cancer of the lymphatic system, Burkitt's lymphoma, can ... malaria parasite. ,The study was conducted ... Qijun Chen at the Karolinska Institute in Stockholm, Sweden. ... of children in equatorial Africa causing terrible suffering. In ...
... discovered a potential new target, Akt2/PKB, a fat metabolism regulatory ... type 2 diabetes. ,The study was conducted ... at the University of Pennsylvania School of Medicine. ... to signal the liver to stop forming glucose and burn ...
... of a tree in Shimla could land you in jail for ... implemented in this hill station. ,Official sources said ... Forest Protection Act that awaits the government nod. ,The ... the gradual depletion of green cover in the town has caused ...
... greenest and cleanest city was not enough, Chandigarh is all set ... the first smoke-free city in the country. ,The ... by July 1. ,The joint capital of Punjab and ... buildings to ensure that smoking is restricted and the general public ...
... Army is to conduct psychological tests on its recruits in ... fratricides that have occurred in the past few years, a ... tests (being introduced from October), we would be able to ... a given situation and the ratio of positive to negative ...
Cached Medicine News:Health News:Fluctuations in Ocean Salinity Could Forewarn of Climate Change 2Health News:Chandigarh to Become India's First Smoke-free City 2Health News:Army to Conduct Psychological Tests During Recruits to Curb Suicides 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
... Signature is a state of the ... integrates blood, sterile body fluid and ... microbiology workstation with comprehensive capabilities. It ... and where expanded flexibility in operating ...
... The BacT/Alert 3D Select ... art, automated microbial detection system ... fluid and mycobacteria culturing. This ... data management or laboratory information ...
Medicine Products: